Sugi Predict

Sugi Predict / Compounds / SCHEMBL615686

SCHEMBL615686

SCHEMBL615686

CCOC(=O)CN(c1ccc2c(c1)sc(=O)n2CC(=O)OCC)S(=O)(=O)c1cccc(Cl)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.38
▸ HPGD P15428 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ SAE1 Q9UBE0 1/20 0.38
▸ UBA2 Q9UBT2 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ TP53 P04637 3/20 0.37
▸ TDP1 Q9NUW8 2/20 0.36
▸ F2 P00734 1/20 0.36
▸ NPSR1 Q6W5P4 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13224707 0.76 HCRTR2 (0.43) HCRTR2ALDH1A1TP53
SCHEMBL11106271 0.71 ALDH1A1 (0.44) ALDH1A1HPGDKDM4EMAPTMEN1
SCHEMBL11102330 0.71 APOBEC3A (0.53) ALDH1A1KDM4EMAPTTDP1F2
SCHEMBL615492 0.69 PKM (0.42) KDM4EMAPTTP53
SCHEMBL145367 0.69 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL29512501 0.69 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4616232 0.68 TDP1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL11112305 0.67 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL11103436 0.67 APOBEC3A (0.46) ALDH1A1HPGDKDM4EMAPTMEN1
SCHEMBL11103716 0.67 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 — — US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 — — US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 — — EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 — — US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 HCRTR2 376/4885ALDH1A1 236/4885HPGD 114/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 HCRTR2 81/4885ALDH1A1 1319/4885HPGD 2152/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 HCRTR2 81/4885ALDH1A1 1319/4885HPGD 2152/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 HCRTR2 73/4885ALDH1A1 553/4885HPGD 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.